On Monday, Humacyte Inc (NASDAQ: HUMA) opened lower -6.67% from the last session, before settling in for the closing price of $1.35. Price fluctuations for HUMA have ranged from $1.30 to $9.97 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 39.23% at the time writing. With a float of $125.85 million, this company’s outstanding shares have now reached $130.03 million.
Let’s determine the extent of company efficiency that accounts for 220 employees. In terms of profitability, gross margin is 0.0%, operating margin of -1582.71%, and the pretax margin is 0.0%.
Humacyte Inc (HUMA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Humacyte Inc is 18.87%, while institutional ownership is 27.75%. The most recent insider transaction that took place on Dec 04 ’24, was worth 20,181. In this transaction Director of this company bought 4,600 shares at a rate of $4.39, taking the stock ownership to the 16,950 shares. Before that another transaction happened on Nov 19 ’24, when Company’s President, CEO and Director bought 1,797 for $4.44, making the entire transaction worth $7,979. This insider now owns 243,851 shares in total.
Humacyte Inc (HUMA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 39.23% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Check out the current performance indicators for Humacyte Inc (HUMA). In the past quarter, the stock posted a quick ratio of 2.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.26, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.33 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Looking closely at Humacyte Inc (NASDAQ: HUMA), its last 5-days average volume was 7.06 million, which is a jump from its year-to-date volume of 3.34 million. As of the previous 9 days, the stock’s Stochastic %D was 5.96%. Additionally, its Average True Range was 0.28.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 1.43%, which indicates a significant decrease from 3.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 158.17% in the past 14 days, which was higher than the 111.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.2534, while its 200-day Moving Average is $5.0288. However, in the short run, Humacyte Inc’s stock first resistance to watch stands at $1.3267. Second resistance stands at $1.3933. The third major resistance level sits at $1.4667. If the price goes on to break the first support level at $1.1867, it is likely to go to the next support level at $1.1133. Now, if the price goes above the second support level, the third support stands at $1.0467.
Humacyte Inc (NASDAQ: HUMA) Key Stats
There are currently 144,843K shares outstanding in the company with a market cap of 195.45 million. Presently, the company’s annual sales total 0 K according to its annual income of -148,700 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -20,940 K.
